MyFinsight
Home
About
Contact
nvax: the income statement
Download
Download image
Net income (loss)
-$202,379K
(-66.84%↓ Y/Y)
Income tax expense
(benefit)
-$657K
(36.34%↑ Y/Y)
Supply Sales
$13,774K
Income (loss) before
income tax expense
-$203,036K
(-65.97%↓ Y/Y)
Other income, net
$9,178K
(-42.36%↓ Y/Y)
Licensing Royalties And
Other
$57,003K
Product
$13,442K
Nuvaxovid Sales
-$332K
Loss on debt
extinguishment
-$28,714K
Interest expense
$5,482K
(29.41%↑ Y/Y)
Income (loss) from
operations
-$178,018K
(-32.83%↓ Y/Y)
Total revenue
$70,445K
(-16.64%↓ Y/Y)
Total expenses
$248,463K
(13.70%↑ Y/Y)
Impairment of assets held
for sale
$97,038K
Selling, general, and
administrative
$31,655K
(-55.26%↓ Y/Y)
Research and development
$98,274K
(12.75%↑ Y/Y)
Cost of sales
$21,496K
(-64.54%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
NOVAVAX INC (NVAX)
NOVAVAX INC (NVAX)